Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine

Journal of Leukocyte Biology

Volumn 86, Issue 4, 2009, Pages 779-793

  Haut, Larissa Herkenhoff ^a,b   Ertl, Hildegund C J ^b  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b WISTAR INSTITUTE   (United States)

Author keywords

Adenovirus vectors; Animal models; Correlates of protection; STEP trial

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL VECTOR; DNA VACCINE; EPITOPE; GAG PROTEIN; GLYCOPROTEIN E1; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; NEF PROTEIN; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; PLASMID VECTOR; POL PROTEIN; PROTEINASE; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENO ASSOCIATED VIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LOSS; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG SAFETY; ELECTROPORATION; GENE DELETION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN ADENOVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; RHESUS MONKEY; SEROTYPE; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS LIKE AGENT; VIRUS LOAD; VIRUS RECOMBINATION; VIRUS TRANSCRIPTION; VIRUS TRANSMISSION;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HIV-1; HUMANS; T-LYMPHOCYTES;

ADENOVIRIDAE; ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70349647523     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0209094     Document Type: Review

References (158)

1. Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., Del Rio, C., McElrath, M. J., Casimiro, D. R., Gottesdiener, K. M., Chodakewitz, J. A., Corey, L., Robertson, M. N. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP Study): a double-blind, randomized, placebo- controlled, test-of-concept trial. Lancet 372, 1881-1893.
2. Pantaleo, G. (2008) HIV-1 T-cell vaccines: evaluating the next step. Lancet Infect. Dis. 8, 82-83.
3. Hu, S. L., Stamatatos, L. (2007) Prospects of HIV env modification as an approach to HIV vaccine design. Curr. HIV Res. 5, 507-513.
4. Roux, K. H., Taylor, K. A. (2007) AIDS virus envelope spike structure. Curr. Opin. Struct. Biol. 17, 244-252.
5. Emini, E. A., Weiner, D. B. (2004) AIDS vaccines. Expert Rev. Vaccines 3, S1-S2.
6. McMichael, A. J. (2006) HIV vaccines. Annu. Rev. Immunol. 24, 227-255.
7. Shiver, J. W., Fu, T. M., Chen, L., Casimiro, D. R., Davies, M. E., Evans, R. K., Zhang, Z. Q., Simon, A. J., Trigona, W. L., Dubey, S. A., et al. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335. (Pubitemid 34087555)
8. Betts, M. R., Nason, M. C., West, S. M., De Rosa, S. C., Migueles, S. A., Abraham, J., Lederman, M. M., Benito, J. M., Goepfert, P. A., Connors, M., Roederer, M., Koup, R. A. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107, 4781-4789. (Pubitemid 43882629)
9. Emu, B., Sinclair, E., Hatano, H., Ferre, A., Shacklett, B., Martin, J. N., McCune, J. M., Deeks, S. G. (2008) HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J. Virol. 82, 5398-5407. (Pubitemid 351705247)
10. Miller, C. J., Li, Q., Abel, K., Kim, E. Y., Ma, Z. M., Wietgrefe, S., La Franco-Scheuch, L., Compton, L., Duan, L., Shore, M. D., Zupancic, M., Busch, M., Carlis, J., Wolinsky, S., Haase, A. T. (2005) Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 79, 9217-9227. (Pubitemid 40934833)
11. Sleasman, J. W., Goodenow, M. M. (2003) 13. HIV-1 infection. J. Allergy Clin. Immunol. 111, S582-S592.
12. Nguyen, V. K., Ako, C. Y., Niamba, P., Sylla, A., Tiendrebeogo, I. (2007) Adherence as therapeutic citizenship: impact of the history of access to antiretroviral drugs on adherence to treatment. AIDS 21 (Suppl. 5), S31-S35. (Pubitemid 350294904)
13. Chen, L. F., Hoy, J., Lewin, S. R. (2007) Ten years of highly active antiretroviral therapy for HIV infection. Med. J. Aust. 186, 146-151. (Pubitemid 46331200)
14. Mc Cann, C. M., Song, R. J., Ruprecht, R. M. (2005) Antibodies: can they protect against HIV infection? Curr. Drug Targets Infect. Disord. 5, 95-111.
15. Rasmussen, R. A., Hofmann-Lehmann, R., Li, P. L., Vlasak, J., Schmitz, J. E., Reimann, K. A., Kuroda, M. J., Letvin, N. L., Montefiori, D. C., McClure, H. M., Ruprecht, R. M. (2002) Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques. AIDS 16, 829-838. (Pubitemid 34409006)
16. Hirbod, T., Kaul, R., Reichard, C., Kimani, J., Ngugi, E., Bwayo, J. J., Nagelkerke, N., Hasselrot, K., Li, B., Moses, S., MacDonald, K. S., Broliden, K. (2008) HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 22, 727-735.
17. Mazzoli, S., Trabattoni, D., Lo Caputo, S., Piconi, S., Ble, C., Meacci, F., Ruzzante, S., Salvi, A., Semplici, F., Longhi, R., Fusi, M. L., Tofani, N., Biasin, M., Villa, M. L., Mazzotta, F., Clerici, M. (1997) HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med. 3, 1250-1257. (Pubitemid 27508826)
18. Pinter, A. (2007) Roles of HIV-1 env variable regions in viral neutralization and vaccine development. Curr. HIV Res. 5, 542-553.
19. Baker, B. M., Block, B. L., Rothchild, A. C., Walker, B. D. (2009) Elite control of HIV infection: implications for vaccine design. Expert Opin. Biol. Ther. 9, 55-69.
20. Pereyra, F., Addo, M. M., Kaufmann, D. E., Liu, Y., Miura, T., Rathod, A., Baker, B., Trocha, A., Rosenberg, R., Mackey, E., Ueda, P., Lu, Z., Cohen, D., Wrin, T., Petropoulos, C. J., Rosenberg, E. S., Walker, B. D. (2008) Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197, 563-571. (Pubitemid 351321534)
21. Goudsmit, J., Bogaards, J. A., Jurriaans, S., Schuitemaker, H., Lange, J. M., Coutinho, R. A., Weverling, G. J. (2002) Naturally HIV-1 sero-converters with lowest viral load have best prognosis, but in time lose control of viremia. AIDS 16, 791-793. (Pubitemid 34274471)
22. Miura, T., Brockman, M. A., Schneidewind, A., Lobritz, M., Pereyra, F., Rathod, A., Block, B. L., Brumme, Z. L., Brumme, C. J., Baker, B., Rothchild, A. C., Li, B., Trocha, A., Cutrell, E., Frahm, N., Brander, C., Toth, I., Arts, E. J., Allen, T. M., Walker, B. D. (2009) Hla-B57/B*5801 HIV-1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong Ctl recognition. J. Virol. 83, 2743-2755.
23. Koup, R. A., Ho, D. D. (1994) Shutting down HIV. Nature 370, 416.
24. Jin, X., Bauer, D. E., Tuttleton, S. E., Lewin, S., Gettie, A., Blanchard, J., Irwin, C. E., Safrit, J. T., Mittler, J., Weinberger, L., Kostrikis, L. G., Zhang, L., Perelson, A. S., Ho, D. D. (1999) Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus- infected macaques. J. Exp. Med. 189, 991-998. (Pubitemid 29149355)
25. Schmitz, J. E., Johnson, R. P., McClure, H. M., Manson, K. H., Wyand, M. S., Kuroda, M. J., Lifton, M. A., Khunkhun, R. S., McEvers, K. J., Gillis, J., Piatak, M., Lifson, J. D., Grosschupff, G., Racz, P., Tenner-Racz, K., Rieber, E. P., Kuus-Reichel, K., Gelman, R. S., Letvin, N. L., Montefiori, D. C., Ruprecht, R. M., Desrosiers, R. C., Reimann, K. A. (2005) Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239Δ3-vaccinated rhesus macaques. J. Virol. 79, 8131-8141. (Pubitemid 40853516)
26. Sankaran, S., Guadalupe, M., Reay, E., George, M. D., Flamm, J., Prindiville, T., Dandekar, S. (2005) Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc. Natl. Acad. Sci. USA 102, 9860-9865. (Pubitemid 40993658)
27. Arthos, J., Cicala, C., Martinelli, E., Macleod, K., Van Ryk, D., Wei, D., Xiao, Z., Veenstra, T. D., Conrad, T. P., Lempicki, R. A., McLaughlin, S., Pascuccio, M., Gopaul, R., McNally, J., Cruz, C. C., Censoplano, N., Chung, E., Reitano, K. N., Kottilil, S., Goode, D. J., Fauci, A. S. (2008) HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9, 301-309. (Pubitemid 351267327)
28. Douek, D. C., Roederer, M., Koup, R. A. (2008) Emerging concepts in the immunopathogenesis of AIDS. Annu. Rev. Med. 60, 471-484.
29. Brenchley, J. M., Douek, D. C. (2008) HIV infection and the gastrointestinal immune system. Mucosal Immunol. 1, 23-30.
30. Silvestri, G. (2008) AIDS pathogenesis: a tale of two monkeys. J. Med. Primatol. 37 (Suppl. 2), 6-12.
31. Silvestri, G. (2009) Immunity in natural SIV infections. J. Intern. Med. 265, 97-109.
32. Boyer, J. D., Robinson, T. M., Kutzler, M. A., Vansant, G., Hokey, D. A., Kumar, S., Parkinson, R., Wu, L., Sidhu, M. K., Pavlakis, G. N., Felber, B. K., Brown, C., Silvera, P., Lewis, M. G., Monforte, J., Waldmann, T. A., Eldridge, J., Weiner, D. B. (2007) Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc. Natl. Acad. Sci. USA 104, 18648-18653. (Pubitemid 350210751)
33. Egan, M. A., Chong, S. Y., Megati, S., Montefiori, D. C., Rose, N. F., Boyer, J. D., Sidhu, M. K., Quiroz, J., Rosati, M., Schadeck, E. B., Pavlakis, G. N., Weiner, D. B., Rose, J. K., Israel, Z. R., Udem, S. A., Eldridge, J. H. (2005) Priming with plasmid DNAs expressing interleukin- 12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res. Hum. Retroviruses 21, 629-643. (Pubitemid 41113651)
34. Suh, Y. S., Park, K. S., Sauermann, U., Franz, M., Norley, S., Wilfingseder, D., Stoiber, H., Fagrouch, Z., Heeney, J., Hunsmann, G., Stahl-Hennig, C., Sung, Y. C. (2006) Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model. Vaccine 24, 1811-1820. (Pubitemid 43238262)
35. Boyer, J. D., Robinson, T. M., Maciag, P. C., Peng, X., Johnson, R. S., Pavlakis, G., Lewis, M. G., Shen, A., Siliciano, R., Brown, C. R., Weiner, D. B., Paterson, Y. (2005) DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology 333, 88-101. (Pubitemid 40222193)
36. Bertley, F. M., Kozlowski, P. A., Wang, S. W., Chappelle, J., Patel, J., Sonuyi, O., Mazzara, G., Montefiori, D., Carville, A., Mansfield, K. G., Aldovini, A. (2004) Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J. Immunol. 172, 3745-3757. (Pubitemid 38337959)
37. Horton, H., Vogel, T. U., Carter, D. K., Vielhuber, K., Fuller, D. H., Shipley, T., Fuller, J. T., Kunstman, K. J., Sutter, G., Montefiori, D. C., Erfle, V., Desrosiers, R. C., Wilson, N., Picker, L. J., Wolinsky, S. M., Wang, C., Allison, D. B., Watkins, D. I. (2002) Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J. Virol. 76, 7187-7202. (Pubitemid 41246232)
38. Hel, Z., Nacsa, J., Tryniszewska, E., Tsai, W. P., Parks, R. W., Montefiori, D. C., Felber, B. K., Tartaglia, J., Pavlakis, G. N., Franchini, G. (2002) Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J. Immunol. 169, 4778-4787. (Pubitemid 35217140)
39. Demberg, T., Boyer, J. D., Malkevich, N., Patterson, L. J., Venzon, D., Summers, E. L., Kalisz, I., Kalyanaraman, V. S., Lee, E. M., Weiner, D. B., Robert-Guroff, M. (2008) Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge. J. Virol. 82, 10911-10921. (Pubitemid 352691169)
40. Casimiro, D. R., Wang, F., Schleif, W. A., Liang, X., Zhang, Z. Q., Tobery, T. W., Davies, M. E., McDermott, A. B., O'Connor, D. H., Fridman, A., et al. (2005) Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing gag. J. Virol. 79, 15547-15555. (Pubitemid 43032336)
41. Letvin, N. L., Mascola, J. R., Sun, Y., Gorgone, D. A., Buzby, A. P., Xu, L., Yang, Z. Y., Chakrabarti, B., Rao, S. S., Schmitz, J. E., Montefiori, D. C., Barker, B. R., Bookstein, F. L., Nabel, G. J. (2006) Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312, 1530-1533. (Pubitemid 43865893)
42. Liu, J., O'Brien, K. L., Lynch, D. M., Simmons, N. L., La Porte, A., Riggs, A. M., Abbink, P., Coffey, R. T., Grandpre, L. E., Seaman, M. S., Landucci, G., Forthal, D. N., Montefiori, D. C., Carville, A., Mansfield, K. G., Havenga, M. J., Pau, M. G., Goudsmit, J., Barouch, D. H. (2009) Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457, 87-91.
43. Zhao, J., Pinczewski, J., Gomez-Roman, V. R., Venzon, D., Kalyanaraman, V. S., Markham, P. D., Aldrich, K., Moake, M., Montefiori, D. C., Lou, Y., Pavlakis, G. N., Robert-Guroff, M. (2003) Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. J. Virol. 77, 8354-8365. (Pubitemid 36871464)
44. McKenna, P. M., Koser, M. L., Carlson, K. R., Montefiori, D. C., Letvin, N. L., Papaneri, A. B., Pomerantz, R. J., Dietzschold, B., Silvera, P., McGettigan, J. P., Schnell, M. J. (2007) Highly attenuated rabies virusbased vaccine vectors expressing simian-human immunodeficiency virus89.6P env and simian immunodeficiency virusmac239 gag are safe in rhesus macaques and protect from an AIDS-like disease. J. Infect. Dis. 195, 980-988. (Pubitemid 46452103)
45. Hansen, S. G., Vieville, C., Whizin, N., Coyne-Johnson, L., Siess, D. C., Drummond, D. D., Legasse, A. W., Axthelm, M. K., Oswald, K., Trubey, C. M., Piatak Jr., M., Lifson, J. D., Nelson, J. A., Jarvis, M. A., Picker, L. J. (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15, 293-299.
46. Barouch, D. H., Fu, T. M., Montefiori, D. C., Lewis, M. G., Shiver, J. W., Letvin, N. L. (2001) Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. Immunol. Lett. 79, 57-61.
47. Doria-Rose, N. A., Ohlen, C., Polacino, P., Pierce, C. C., Hensel, M. T., Kuller, L., Mulvania, T., Anderson, D., Greenberg, P. D., Hu, S. L., Haigwood, N. L. (2003) Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J. Virol. 77, 11563-11577. (Pubitemid 37271655)
48. Egan, M. A., Chong, S. Y., Rose, N. F., Megati, S., Lopez, K. J., Schadeck, E. B., Johnson, J. E., Masood, A., Piacente, P., Druilhet, R. E., Barras, P. W., Hasselschwert, D. L., Reilly, P., Mishkin, E. M., Montefiori, D. C., Lewis, M. G., Clarke, D. K., Hendry, R. M., Marx, P. A., Eldridge, J. H., Udem, S. A., Israel, Z. R., Rose, J. K. (2004) Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 env and SIV gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res. Hum. Retroviruses 20, 989-1004. (Pubitemid 39369705)
49. Fultz, P. N., Stallworth, J., Porter, D., Novak, M., Anderson, M. J., Morrow, C. D. (2003) Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease. Virology 315, 425-437. (Pubitemid 37324633)
50. Kim, J. J., Yang, J. S., Nottingham, L. K., Lee, D. J., Lee, M., Manson, K. H., Wyand, M. S., Boyer, J. D., Ugen, K. E., Weiner, D. B. (2001) Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization. Virology 285, 204-217. (Pubitemid 32641882)
51. Lifson, J. D., Rossio, J. L., Piatak Jr., M., Bess Jr., J., Chertova, E., Schneider, D. K., Coalter, V. J., Poore, B., Kiser, R. F., Imming, R. J., Scarzello, A. J., Henderson, L. E., Alvord, W. G., Hirsch, V. M., Benveniste, R. E., Arthur, L. O. (2004) Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res. Hum. Retroviruses 20, 772-787. (Pubitemid 39037509)
52. Tang, Y., Villinger, F., Staprans, S. I., Amara, R. R., Smith, J. M., Herndon, J. G., Robinson, H. L. (2002) Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges. J. Virol. 76, 10147-10154.
53. Feinberg, M. B., Moore, J. P. (2002) AIDS vaccine models: challenging challenge viruses. Nat. Med. 8, 207-210.
54. Song, R. J., Chenine, A. L., Rasmussen, R. A., Ruprecht, C. R., Mirshahidi, S., Grisson, R. D., Xu, W., Whitney, J. B., Goins, L. M., Ong, H., Li, P. L., Shai-Kobiler, E., Wang, T., McCann, C. M., Zhang, H., Wood, C., Kankasa, C., Secor, W. E., McClure, H. M., Strobert, E., Else, J. G., Ruprecht, R. M. (2006) Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C env. J. Virol. 80, 8729-8738. (Pubitemid 44384882)
55. Vieillard, V., Habib, R. E., Brochard, P., Delache, B., Bovendo, H. F., Calvo, J., Morin, J., Picq, I., Martinon, F., Vaslin, B., Le Grand, R., Debré, P. (2008) CCR5 or CXCR4 use influences the relationship between CD4 cell depletion, NKp44L expression and NK cytotoxicity in SHIVinfected macaques. AIDS 22, 185-192.
56. Crotty, S., Miller, C. J., Lohman, B. L., Neagu, M. R., Compton, L., Lu, D., Lu, F. X., Fritts, L., Lifson, J. D., Andino, R. (2001) Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J. Virol. 75, 7435-7452. (Pubitemid 32738002)
57. Martinon, F., Brochard, P., Ripaux, M., Delache, B., Auregan, G., Vaslin, B., Le Grand, R. (2008) Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus. Vaccine 26, 532-545.
58. Murphy, C. G., Lucas, W. T., Means, R. E., Czajak, S., Hale, C. L., Lifson, J. D., Kaur, A., Johnson, R. P., Knipe, D. M., Desrosiers, R. C. (2000) Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J. Virol. 74, 7745-7754. (Pubitemid 30641618)
59. Polacino, P., Stallard, V., Montefiori, D. C., Brown, C. R., Richardson, B. A., Morton, W. R., Benveniste, R. E., Hu, S. L. (1999) Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. J. Virol. 73, 3134-3146. (Pubitemid 29135704)
60. Zhou, Q., Hidajat, R., Peng, B., Venzon, D., Aldrich, M. K., Richardson, E., Lee, E. M., Kalyanaraman, V. S., Grimes, G., Gomez-Roman, V. R., Summers, L. E., Malkevich, N., Robert-Guroff, M. (2007) Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). Vaccine 25, 8021-8035. (Pubitemid 47632993)
61. Johnson, R. P., Desrosiers, R. C. (1998) Protective immunity induced by live attenuated simian immunodeficiency virus. Curr. Opin. Immunol. 10, 436-443. (Pubitemid 28393827)
62. Mansfield, K., Lang, S. M., Gauduin, M. C., Sanford, H. B., Lifson, J. D., Johnson, R. P., Desrosiers, R. C. (2008) Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J. Virol. 82, 4135-4148.
63. Shacklett, B. L., Shaw, K. E., Adamson, L. A., Wilkens, D. T., Cox, C. A., Montefiori, D. C., Gardner, M. B., Sonigo, P., Luciw, P. A. (2002) Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251. J. Virol. 76, 11365-11378. (Pubitemid 35231292)
64. Ahmed, R. K., Nilsson, C., Wang, Y., Lehner, T., Biberfeld, G., Thorstensson, R. (1999) β-Chemokine production in macaques vaccinated with live attenuated virus correlates with protection against simian immunodeficiency virus (SIVsm) challenge. J. Gen. Virol. 80, 1569-1574. (Pubitemid 29319846)
65. Clements, J. E., Montelaro, R. C., Zink, M. C., Amedee, A. M., Miller, S., Trichel, A. M., Jagerski, B., Hauer, D., Martin, L. N., Bohm, R. P., et al. (1995) Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J. Virol. 69, 2737-2744.
66. McDermott, A. B., Mitchen, J., Piaskowski, S., De Souza, I., Yant, L. J., Stephany, J., Furlott, J., Watkins, D. I. (2004) Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J. Virol. 78, 3140-3144. (Pubitemid 38314372)
67. Loffredo, J. T., Friedrich, T. C., Leon, E. J., Stephany, J. J., Rodrigues, D. S., Spencer, S. P., Bean, A. T., Beal, D. R., Burwitz, B. J., Rudersdorf, R. A., Wallace, L. T., Piaskowski, S. M., May, G. E., Sidney, J., Gostick, E., Wilson, N. A., Price, D. A., Kallas, E. G., Piontkivska, H., Hughes, A. L., Sette, A., Watkins, D. I. (2007) CD8+ T cells from SIV elite controller macaques recognize Mamu-B*08-bound epitopes and select for widespread viral variation. PLoS ONE 2, e1152. (Pubitemid 351637971)
68. Goepfert, P. A., Tomaras, G. D., Horton, H., Montefiori, D., Ferrari, G., Deers, M., Voss, G., Koutsoukos, M., Pedneault, L., Vandepapeliere, P., McElrath, M. J., Spearman, P., Fuchs, J. D., Koblin, B. A., Blattner, W. A., Frey, S., Baden, L. R., Harro, C., Evans, T. (2007) Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 25, 510-518. (Pubitemid 44856093)
69. Crooks, E. T., Moore, P. L., Franti, M., Cayanan, C. S., Zhu, P., Jiang, P., de Vries, R. P., Wiley, C., Zharkikh, I., Schulke, N., Roux, K. H., Monte- fiori, D. C., Burton, D. R., Binley, J. M. (2007) A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366, 245-262.
70. Brave, A., Hallengard, D., Malm, M., Blazevic, V., Rollman, E., Stanescu, I., Krohn, K. (2009) Combining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV-1 immune responses. Vaccine 27, 184-186.
71. Huang, Y., Krasnitz, M., Rabadan, R., Witten, D. M., Song, Y., Levine, A. J., Ho, D. D., Robins, H. (2008) A recoding method to improve the humoral immune response to an HIV DNA vaccine. PLoS ONE 3, e3214.
72. Kennedy, J. S., Co, M., Green, S., Longtine, K., Longtine, J., O'Neill, M. A., Adams, J. P., Rothman, A. L., Yu, Q., Johnson-Leva, R., Pal, R., Wang, S., Lu, S., Markham, P. (2008) The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 26, 4420-4424.
73. Megati, S., Garcia-Hand, D., Cappello, S., Roopchand, V., Masood, A., Xu, R., Luckay, A., Chong, S. Y., Rosati, M., Sackitey, S., Weiner, D. B., Felber, B. K., Pavlakis, G. N., Israel, Z. R., Smith, L. R., Eldridge, J. H., Sidhu, M. K., Egan, M. A. (2008) Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses. Vaccine 26, 5083-5094.
74. Xu, R., Megati, S., Roopchand, V., Luckay, A., Masood, A., Garcia-Hand, D., Rosati, M., Weiner, D. B., Felber, B. K., Pavlakis, G. N., Sidhu, M. K., Eldridge, J. H., Egan, M. A. (2008) Comparative ability of various plasmid- based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 26, 4819-4829.
75. Yan, J., Hokey, D. A., Morrow, M. P., Corbitt, N., Harris, K., Harris, D., Weiner, D. B. (2009) Novel SIVmac DNA vaccines encoding Env, Pol and Gag consensus proteins elicit strong cellular immune responses in cynomolgus macaques. Vaccine 27, 3260-3266.
76. Chen, Z., Huang, Y., Zhao, X., Ba, L., Zhang, W., Ho, D. D. (2008) Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B′. J. Acquir. Immune Defic. Syndr. 47, 412-421.
77. Liniger, M., Zuniga, A., Morin, T. N., Combardiere, B., Marty, R., Wiegand, M., Ilter, O., Knuchel, M., Naim, H. Y. (2009) Recombinant measles viruses expressing single or multiple antigens of human immunode- ficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine 27, 3299-3305.
78. Slobod, K. S., Lockey, T. D., Howlett, N., Srinivas, R. V., Rencher, S. D., Freiden, P. J., Doherty, P. C., Hurwitz, J. L. (2004) Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur. J. Clin. Microbiol. Infect. Dis. 23, 106-110. (Pubitemid 38392137)
79. Tatsis, N., Ertl, H. C. (2004) Adenoviruses as vaccine vectors. Mol. Ther. 10, 616-629.
80. Xin, K. Q., Urabe, M., Yang, J., Nomiyama, K., Mizukami, H., Hamajima, K., Nomiyama, H., Saito, T., Imai, M., Monahan, J., Okuda, K., Ozawa, K., Okuda, K. (2001) A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum. Gene Ther. 12, 1047-1061. (Pubitemid 32692421)
81. Guimaraes-Walker, A., Mackie, N., McCormack, S., Hanke, T., Schmidt, C., Gilmour, J., Barin, B., McMichael, A., Weber, J., Legg, K., Babiker, A., Hayes, P., Gotch, F., Smith, C., Dally, L., Dorrell, L., Cebere, I., Kay, R., Winstone, N., Moore, S., Goonetilleke, N., Fast, P. (2008) Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 26, 6671-6677.
82. Yu, S., Feng, X., Shu, T., Matano, T., Hasegawa, M., Wang, X., Ma, H., Li, H., Li, Z., Zeng, Y. (2008) Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine 26, 6124-6131.
83. Mulligan, M. J., Russell, N. D., Celum, C., Kahn, J., Noonan, E., Monte- fiori, D. C., Ferrari, G., Weinhold, K. J., Smith, J. M., Amara, R. R., Robinson, H. L. (2006) Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res. Hum. Retroviruses 22, 678-683.
84. Barouch, D. H., Santra, S., Steenbeke, T. D., Zheng, X. X., Perry, H. C., Davies, M. E., Freed, D. C., Craiu, A., Strom, T. B., Shiver, J. W., Letvin, N. L. (1998) Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J. Immunol. 161, 1875-1882. (Pubitemid 28387609)
85. Jones, N. G., DeCamp, A., Gilbert, P., Peterson, M. L., Gurwith, M., Cao, H. (2009) AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine 27, 1136-1140.
86. Lindenburg, C. E., Stolte, I., Langendam, M. W., Miedema, F., Williams, I. G., Colebunders, R., Weber, J. N., Fisher, M., Coutinho, R. A. (2002) Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 20, 2343-2347.
87. Johnson, P. R., Schnepp, B. C., Connell, M. J., Rohne, D., Robinson, S., Krivulka, G. R., Lord, C. I., Zinn, R., Montefiori, D. C., Letvin, N. L., Clark, K. R. (2005) Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J. Virol. 79, 955-965. (Pubitemid 40053879)
88. Pinto, A. R., Fitzgerald, J. C., Giles-Davis, W., Gao, G. P., Wilson, J. M., Ertl, H. C. (2003) Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J. Immunol. 171, 6774-6779. (Pubitemid 37532111)
89. Fitzgerald, J. C., Gao, G. P., Reyes-Sandoval, A., Pavlakis, G. N., Xiang, Z. Q., Wlazlo, A. P., Giles-Davis, W., Wilson, J. M., Ertl, H. C. (2003) A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170, 1416-1422. (Pubitemid 36139509)
90. Nanda, A., Lynch, D. M., Goudsmit, J., Lemckert, A. A., Ewald, B. A., Sumida, S. M., Truitt, D. M., Abbink, P., Kishko, M. G., Gorgone, D. A., Lifton, M. A., Shen, L., Carville, A., Mansfield, K. G., Havenga, M. J., Barouch, D. H. (2005) Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J. Virol. 79, 14161-14168. (Pubitemid 41552714)
91. Russell, N. D., Graham, B. S., Keefer, M. C., McElrath, M. J., Self, S. G., Weinhold, K. J., Montefiori, D. C., Ferrari, G., Horton, H., Tomaras, G. D., Gurunathan, S., Baglyos, L., Frey, S. E., Mulligan, M. J., Harro, C. D., Buchbinder, S. P., Baden, L. R., Blattner, W. A., Koblin, B. A., Corey, L. (2007) Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J. Acquir. Immune Defic. Syndr. 44, 203-212. (Pubitemid 46292224)
92. Emery, S., Workman, C., Puls, R. L., Bloch, M., Baker, D., Bodsworth, N., Anderson, J., Crowe, S. M., French, M. A., Hoy, J., Aichelburg, A., Ward, L. D., Boyle, D. B., Law, M. G., Kelleher, A. D., Cooper, D. A. (2005) Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-γ in HIV-1 infected subjects. Hum. Vaccin. 1, 232-238.
93. Sealy, R., Slobod, K. S., Flynn, P., Branum, K., Surman, S., Jones, B., Freiden, P., Lockey, T., Howlett, N., Hurwitz, J. L. (2009) Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine. Int. Rev. Immunol. 28, 49-68.
94. Kawada, M., Tsukamoto, T., Yamamoto, H., Iwamoto, N., Kurihara, K., Takeda, A., Moriya, C., Takeuchi, H., Akari, H., Matano, T. (2008) Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J. Virol. 82, 10199-10206.
95. Guerbois, M., Moris, A., Combredet, C., Najburg, V., Ruffie, C., Fevrier, M., Cayet, N., Brandler, S., Schwartz, O., Tangy, F. (2009) Live attenuated measles vaccine expressing HIV-1 gag virus like particles covered with gp160ΔV1V2 is strongly immunogenic. Virology 388, 191-203.
96. Berglund, P., Quesada-Rolander, M., Putkonen, P., Biberfeld, G., Thorstensson, R., Liljestrom, P. (1997) Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res. Hum. Retroviruses 13, 1487-1495. (Pubitemid 27500577)
97. Williamson, C., Morris, L., Maughan, M. F., Ping, L. H., Dryga, S. A., Thomas, R., Reap, E. A., Cilliers, T., van Harmelen, J., Pascual, A., Ramjee, G., Gray, G., Johnston, R., Karim, S. A., Swanstrom, R. (2003) Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res. Hum. Retroviruses 19, 133-144. (Pubitemid 36308051)
98. Chen, Y., Helmus, R., McClane, B., Hoffman, R., Watkins, S., Wehrli, T., Gupta, P. (2004) Use of a Clostridium perfringens vector to express high levels of SIV p27 protein for the development of an oral SIV vaccine. Virology 329, 226-233. (Pubitemid 39423973)
99. Kawahara, M. (2008) Recombinant Mycobacterium bovis BCG vector system expressing SIV gag protein stably and persistently induces antigen-specific humoral immune response concomitant with IFN γ response, even at three years after immunization. Clin. Immunol. 129, 492-498.
100. Hovav, A. H., Cayabyab, M. J., Panas, M. W., Santra, S., Greenland, J., Geiben, R., Haynes, B. F., Jacobs Jr., W. R., Letvin, N. L. (2007) Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis. J. Virol. 81, 74-83. (Pubitemid 44975148)
101. Jiang, S., Rasmussen, R. A., Nolan, K. M., Frankel, F. R., Lieberman, J., McClure, H. M., Williams, K. M., Babu, U. S., Raybourne, R. B., Strobert, E., Ruprecht, R. M. (2007) Live attenuated Listeria monocytogenes expressing HIV gag: immunogenicity in rhesus monkeys. Vaccine 25, 7470-7479. (Pubitemid 47484002)
102. Kotton, C. N., Lankowski, A. J., Scott, N., Sisul, D., Chen, L. M., Raschke, K., Borders, G., Boaz, M., Spentzou, A., Galan, J. E., Hohmann, E. L. (2006) Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 gag antigen via the Salmonella type III secretion system. Vaccine 24, 6216-6224. (Pubitemid 44247245)
103. Haglund, K., Leiner, I., Kerksiek, K., Buonocore, L., Pamer, E., Rose, J. K. (2002) High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J. Virol. 76, 2730-2738. (Pubitemid 34184859)
104. Letvin, N. L., Huang, Y., Chakrabarti, B. K., Xu, L., Seaman, M. S., Beaudry, K., Korioth-Schmitz, B., Yu, F., Rohne, D., Martin, K. L., Miura, A., Kong, W. P., Yang, Z. Y., Gelman, R. S., Golubeva, O. G., Montefiori, D. C., Mascola, J. R., Nabel, G. J. (2004) Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J. Virol. 78, 7490-7497. (Pubitemid 38915894)
105. Mascola, J. R., Sambor, A., Beaudry, K., Santra, S., Welcher, B., Louder, M. K., Vancott, T. C., Huang, Y., Chakrabarti, B. K., Kong, W. P., Yang, Z. Y., Xu, L., Montefiori, D. C., Nabel, G. J., Letvin, N. L. (2005) Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J. Virol. 79, 771-779. (Pubitemid 40053860)
106. Robinson, H. L., Sharma, S., Zhao, J., Kannanganat, S., Lai, L., Chennareddi, L., Yu, T., Montefiori, D. C., Amara, R. R., Wyatt, L. S., Moss, B. (2007) Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-γ, IL-2, and TNF-α coproducing CD4 and CD8 T cells. AIDS Res. Hum. Retroviruses 23, 1555-1562.
107. Lemckert, A. A., Grimbergen, J., Smits, S., Hartkoorn, E., Holterman, L., Berkhout, B., Barouch, D. H., Vogels, R., Quax, P., Goudsmit, J., Havenga, M. J. (2006) Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J. Gen. Virol. 87, 2891-2899. (Pubitemid 44463897)
108. Liu, J., Ewald, B. A., Lynch, D. M., Denholtz, M., Abbink, P., Lemckert, A. A., Carville, A., Mansfield, K. G., Havenga, M. J., Goudsmit, J., Barouch, D. H. (2008) Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82, 4844-4852. (Pubitemid 351657046)
109. McCoy, K., Tatsis, N., Korioth-Schmitz, B., Lasaro, M. O., Hensley, S. E., Lin, S. W., Li, Y., Giles-Davis, W., Cun, A., Zhou, D., Xiang, Z., Letvin, N. L., Ertl, H. C. (2007) Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol. 81, 6594-6604. (Pubitemid 46878063)
110. Demberg, T., Florese, R. H., Heath, M. J., Larsen, K., Kalisz, I., Kalyanaraman, V. S., Lee, E. M., Pal, R., Venzon, D., Grant, R., Patterson, L. J., Korioth-Schmitz, B., Buzby, A., Dombagoda, D., Montefiori, D. C., Letvin, N. L., Cafaro, A., Ensoli, B., Robert-Guroff, M. (2007) A replication- competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 81, 3414-3427. (Pubitemid 46456650)
111. Patterson, L. J., Prince, G. A., Richardson, E., Alvord, W. G., Kalyan, N., Robert-Guroff, M. (2002) Insertion of HIV-1 genes into Ad4ΔE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion. Virology 292, 107-113. (Pubitemid 34925843)
112. Hokey, D. A., Weiner, D. B. (2006) DNA vaccines for HIV: challenges and opportunities. Springer Semin. Immunopathol. 28, 267-279. (Pubitemid 44764282)
113. Rosati, M., Valentin, A., Jalah, R., Patel, V., von Gegerfelt, A., Bergamaschi, C., Alicea, C., Weiss, D., Treece, J., Pal, R., Markham, P. D., Marques, E. T., August, J. T., Khan, A., Draghia-Akli, R., Felber, B. K., Pavlakis, G. N. (2008) Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 26, 5223-5229.
114. Sandstrom, E., Nilsson, C., Hejdeman, B., Brave, A., Bratt, G., Robb, M., Cox, J., Vancott, T., Marovich, M., Stout, R., Aboud, S., Bakari, M., Pallangyo, K., Ljungberg, K., Moss, B., Earl, P., Michael, N., Birx, D., Mhalu, F., Wahren, B., Biberfeld, G. (2008) Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 198, 1482-1490.
115. Jaoko, W., Nakwagala, F. N., Anzala, O., Manyonyi, G. O., Birungi, J., Nanvubya, A., Bashir, F., Bhatt, K., Ogutu, H., Wakasiaka, S., et al. (2008) Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 26, 2788-2795.
116. Wang, S., Kennedy, J. S., West, K., Montefiori, D. C., Coley, S., Lawrence, J., Shen, S., Green, S., Rothman, A. L., Ennis, F. A., Arthos, J., Pal, R., Markham, P., Lu, S. (2008) Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26, 1098-1110.
117. Graham, F. L., Prevec, L. (1992) Adenovirus-based expression vectors and recombinant vaccines. Biotechnology 20, 363-390.
118. Shaw, G., Morse, S., Ararat, M., Graham, F. L. (2002) Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J. 16, 869-871.
119. Jones, D., Kroos, N., Anema, R., van Montfort, B., Vooys, A., van der Kraats, S., van der Helm, E., Smits, S., Schouten, J., Brouwer, K., Lagerwerf, F., van Berkel, P., Opstelten, D. J., Logtenberg, T., Bout, A. (2003) High-level expression of recombinant IgG in the human cell line PER.C6. Biotechnol. Prog. 19, 163-168. (Pubitemid 36219317)
120. Tatsis, N., Blejer, A., Lasaro, M. O., Hensley, S. E., Cun, A., Tesema, L., Li, Y., Gao, G. P., Xiang, Z. Q., Zhou, D., Wilson, J. M., Ertl, H. C. (2007) A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol. Ther. 15, 608-617. (Pubitemid 46306605)
121. Orlando, J. S., Ornelles, D. A. (2002) E4orf6 variants with separate abilities to augment adenovirus replication and direct nuclear localization of the E1B 55-kilodalton protein. J. Virol. 76, 1475-1487.
122. Burgert, H. G., Ruzsics, Z., Obermeier, S., Hilgendorf, A., Windheim, M., Elsing, A. (2002) Subversion of host defense mechanisms by adenoviruses. Curr. Top. Microbiol. Immunol. 269, 273-318. (Pubitemid 34851538)
123. Tatsis, N., Tesema, L., Robinson, E. R., Giles-Davis, W., McCoy, K., Gao, G. P., Wilson, J. M., Ertl, H. C. (2006) Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 13, 421-429.
124. Catanzaro, A. T., Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L., Martin, J. E., Novik, L., Chakrabarti, B. K., Butman, B. T., Gall, J. G., King, C. R., Andrews, C. A., Sheets, R., Gomez, P. L., Mascola, J. R., Nabel, G. J., Graham, B. S. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194, 1638-1649. (Pubitemid 44901994)
125. Shiver, J. W., Emini, E. A. (2004) Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55, 355-372.
126. Tatsis, N., Fitzgerald, J. C., Reyes-Sandoval, A., Harris-McCoy, K. C., Hensley, S. E., Zhou, D., Lin, S. W., Bian, A., Xiang, Z. Q., Iparraguirre, A., Lopez-Camacho, C., Wherry, E. J., Ertl, H. C. (2007) Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110, 1916-1923. (Pubitemid 47443905)
127. Xiang, Z., Li, Y., Cun, A., Yang, W., Ellenberg, S., Switzer, W. M., Kalish, M. L., Ertl, H. C. (2006) Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 12, 1596-1599. (Pubitemid 44570909)
128. Farina, S. F., Gao, G. P., Xiang, Z. Q., Rux, J. J., Burnett, R. M., Alvira, M. R., Marsh, J., Ertl, H. C., Wilson, J. M. (2001) Replication- defective vector based on a chimpanzee adenovirus. J. Virol. 75, 11603-11613. (Pubitemid 33063252)
129. Rux, J. J., Kuser, P. R., Burnett, R. M. (2003) Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution X-ray crystallographic, molecular modeling, and sequence-based methods. J. Virol. 77, 9553-9566.
130. Hensley, S. E., Giles-Davis, W., McCoy, K. C., Weninger, W., Ertl, H. C. (2005) Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J. Immunol. 175, 6032-6041. (Pubitemid 41508089)
131. Reyes-Sandoval, A., Fitzgerald, J. C., Grant, R., Roy, S., Xiang, Z. Q., Li, Y., Gao, G. P., Wilson, J. M., Ertl, H. C. (2004) Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J. Virol. 78, 7392-7399. (Pubitemid 38915884)
132. Thorner, A. R., Lemckert, A. A., Goudsmit, J., Lynch, D. M., Ewald, B. A., Denholtz, M., Havenga, M. J., Barouch, D. H. (2006) Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J. Virol. 80, 12009-12016. (Pubitemid 44904350)
133. Abbink, P., Lemckert, A. A., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., O'Brien, K. L., Carville, A., Mansfield, K. G., Goudsmit, J., Havenga, M. J., Barouch, D. H. (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81, 4654-4663. (Pubitemid 46668663)
134. Roberts, D. M., Nanda, A., Havenga, M. J., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., Lifton, M. A., Lemckert, A. A., Holterman, L., Chen, B., Dilraj, A., Carville, A., Mansfield, K. G., Goudsmit, J., Barouch, D. H. (2006) Hexonchimaeric adenovirus serotype 5 vectors circumvent pre-existing antivector immunity. Nature 441, 239-243.
135. Flynn, N. M., Forthal, D. N., Harro, C. D., Judson, F. N., Mayer, K. H., Para, M. F. (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654-665.
136. Mehendale, S., van Lunzen, J., Clumeck, N., Rockstroh, J., Vets, E., Johnson, P. R., Anklesaria, P., Barin, B., Boaz, M., Kochhar, S., Lehrman, J., Schmidt, C., Peeters, M., Schwarze-Zander, C., Kabamba, K., Glaunsinger, T., Sahay, S., Thakar, M., Paranjape, R., Gilmour, J., Excler, J. L., Fast, P., Heald, A. E. (2008) A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res. Hum. Retroviruses 24, 873-880. (Pubitemid 351871679)
137. Peters, B. S., Jaoko, W., Vardas, E., Panayotakopoulos, G., Fast, P., Schmidt, C., Gilmour, J., Bogoshi, M., Omosa-Manyonyi, G., Dally, L., Klavinskis, L., Farah, B., Tarragona, T., Bart, P. A., Robinson, A., Pieterse, C., Stevens, W., Thomas, R., Barin, B., McMichael, A. J., McIntyre, J. A., Pantaleo, G., Hanke, T., Bwayo, J. (2007) Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25, 2120-2127. (Pubitemid 46237679)
138. Hirao, L. A., Wu, L., Khan, A. S., Satishchandran, A., Draghia-Akli, R., Weiner, D. B. (2008) Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26, 440-448.
139. Lin, S. W., Hensley, S. E., Tatsis, N., Lasaro, M. O., Ertl, H. C. (2007) Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J. Clin. Invest. 117, 3958-3970. (Pubitemid 350224105)
140. Rerks-Ngarm, S., Brown, A. E., Khamboonruang, C., Thongcharoen, P., Kunasol, P. (2006) HIV/AIDS preventive vaccine "prime-boost" phase III trial: foundations and initial lessons learned from Thailand. AIDS 20, 1471-1479. (Pubitemid 44100207)
141. Corey, L., McElrath, M. J., Kublin, J. G. (2009) Post-step modifications for research on HIV vaccines. AIDS 23, 3-8.
142. Gahery-Segard, H., Pialoux, G., Figueiredo, S., Igea, C., Surenaud, M., Gaston, J., Gras-Masse, H., Levy, J. P., Guillet, J. G. (2003) Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized. J. Virol. 77, 11220-11231. (Pubitemid 37204312)
143. Keefer, M. C., Wolff, M., Gorse, G. J., Graham, B. S., Corey, L., Clements- Mann, M. L., Verani-Ketter, N., Erb, S., Smith, C. M., Belshe, R. B., Wagner, L. J., McElrath, M. J., Schwartz, D. H., Fast, P. (1997) Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 13, 1163-1177. (Pubitemid 27408074)
144. Cleghorn, F., Pape, J. W., Schechter, M., Bartholomew, C., Sanchez, J., Jack, N., Metch, B. J., Hansen, M., Allen, M., Cao, H., Montefiori, D. C., Tomaras, G. D., Gurunathan, S., Eastman, D. J., do Lago, R. F., Jean, S., Lama, J. R., Lawrence, D. N., Wright, P. F. (2007) Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J. Acquir. Immune Defic. Syndr. 46, 222-230.
145. McCormack, S., Stohr, W., Barber, T., Bart, P. A., Harari, A., Moog, C., Ciuffreda, D., Cellerai, C., Cowen, M., Gamboni, R., Burnet, S., Legg, K., Brodnicki, E., Wolf, H., Wagner, R., Heeney, J., Frachette, M. J., Tartaglia, J., Babiker, A., Pantaleo, G., Weber, J. (2008) EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 26, 3162-3174.
146. Priddy, F. H., Brown, D., Kublin, J., Monahan, K., Wright, D. P., Lalezari, J., Santiago, S., Marmor, M., Lally, M., Novak, R. M., Brown, S. J., Kulkarni, P., Dubey, S. A., Kierstead, L. S., Casimiro, D. R., Mogg, R., DiNubile, M. J., Shiver, J. W., Leavitt, R. Y., Robertson, M. N., Mehrotra, D. V., Quirk, E. (2008) Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46, 1769-1781. (Pubitemid 351706778)
147. NIAID (2007) An update regarding the HVTN 502 and HVTN 503 HIV vaccine trials. http://www3.niaid.nih.gov/news/newsreleases/2007/step-update.htm.
148. NIAID (2008) An update concerning the HVTN 503/Phambili HIV vaccine study. http://www3.niaid.nih.gov/news/newsreleases/2008/hvtn503-update.htm.
149. McElrath, M. J., De Rosa, S. C., Moodie, Z., Dubey, S., Kierstead, L., Janes, H., Defawe, O. D., Carter, D. K., Hural, J., Akondy, R., Buchbinder, S. P., Robertson, M. N., Mehrotra, D. V., Self, S. G., Corey, L., Shiver, J. W., Casimiro, D. R. (2008) HIV-1 vaccine-induced immunity in the test-of-concept STEP Study: a case-cohort analysis. Lancet 372, 1894-1905.
150. HVTN (2008) Reshaped scientific agenda involves understanding the clinical and immunological aspects of the Step trial. http://www3.niaid.nih.gov/ topics/HIVAIDS/Research/vaccines/reports/hvtnoct2008.htm.
151. Staprans, S. I., Barry, A. P., Silvestri, G., Safrit, J. T., Kozyr, N., Sumpter, B., Nguyen, H., McClure, H., Montefiori, D., Cohen, J. I., Feinberg, M. B. (2004) Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc. Natl. Acad. Sci. USA 101, 13026-13031. (Pubitemid 39167577)
152. Brichacek, B., Swindells, S., Janoff, E. N., Pirruccello, S., Stevenson, M. (1996) Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J. Infect. Dis. 174, 1191-1199. (Pubitemid 26393896)
153. Staprans, S. I., Hamilton, B. L., Follansbee, S. E., Elbeik, T., Barbosa, P., Grant, R. M., Feinberg, M. B. (1995) Activation of virus replication after vaccination of HIV-1-infected individuals. J. Exp. Med. 182, 1727-1737.
154. Sullivan, P. S., Hanson, D. L., Dworkin, M. S., Jones, J. L., Ward, J. W. (2000) Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS 14, 2781-2785.
155. Veltrop-Duits, L. A., Heemskerk, B., Sombroek, C. C., van Vreeswijk, T., Gubbels, S., Toes, R. E., Melief, C. J., Franken, K. L., Havenga, M., van Tol, M. J., Schilham, M. W. (2006) Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus. Eur. J. Immunol. 36, 2410-2423. (Pubitemid 44420598)
156. Cheng, S. M., Lee, S. G., Ronchetti-Blume, M., Virk, K. P., Mizutani, S., Eichberg, J. W., Davis, A., Hung, P. P., Hirsch, V. M., Chanock, R. M., et al. (1992) Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant. J. Virol. 66, 6721-6727.
157. NIAID (2008) NIAID Will Not Move Forward with the Pave 100 HIV Vaccine Trial. http://www3.niaid.nih.gov/news/newsreleases/2008/pave100.htm.
158. Zuckerman, A., Hamburger, Y., Spira, D. (1967) Active immunization of rats with a cell-free extract of the erythrocytic parasites of Plasmodium berghei. Exp. Parasitol. 21, 84-97.